Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity

CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammato...

Full description

Saved in:
Bibliographic Details
Published in:International journal of peptide research and therapeutics 2019-06, Vol.25 (2), p.535-540
Main Authors: Sadeghian-Rizi, Tahereh, Behdani, Mahdi, Khanahmad, Hossein, Ghasemi-Dehkordi, Pooria, Mirmohammad Sadeghi, Hamid, Jahanian-Najafabadi, Ali
Format: Article
Language:English
Subjects:
Animal Anatomy
Autoimmune diseases
Biochemistry
Biomedical and Life Sciences
Chemokines
CXC chemokines
CXCL10 protein
CXCR3 protein
Enzyme-linked immunosorbent assay
Gel electrophoresis
Histology
Immunization
Immunoglobulin G
Life Sciences
Medical treatment
Membrane reactors
Molecular Medicine
Morphology
Multiple sclerosis
Nanobodies
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Polyclonal antibodies
Polymer Sciences
Protein G
Sodium lauryl sulfate
Therapeutic applications
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663
cites cdi_FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663
container_end_page 540
container_issue 2
container_start_page 535
container_title International journal of peptide research and therapeutics
container_volume 25
creator Sadeghian-Rizi, Tahereh
Behdani, Mahdi
Khanahmad, Hossein
Ghasemi-Dehkordi, Pooria
Mirmohammad Sadeghi, Hamid
Jahanian-Najafabadi, Ali
description CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammatory and autoimmune diseases. It has been put forward as a potential biomarker and therapeutic target in diagnosis and treatment of these diseases. In the present study, production of camel heavy chain antibodies (HCAbs) specific for the CXCL10 is reported. In this regard, recombinant CXCL10 was used for immunization of camel and subsequently the CXCL10 HCAbs were obtained. Afterwards, three subclasses of IgG were separated using protein A and protein G affinity columns, characterized with SDS-PAGE and confirmed for specific binding to the CXCL10 using ELISA. These IgG subclasses successfully recognized CXCL10 and a strong and specific reactivity towards CXCL10 were observed. Therefore, the selected HCAbs and their corresponding expression library could be used to develop a recombinant variable domain of these HCAbs (nanobody or VHH) as a new possible strategy for treatment of multiple sclerosis and other autoimmune diseases.
doi_str_mv 10.1007/s10989-018-9697-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2015882580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2015882580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663</originalsourceid><addsrcrecordid>eNp1kE1LAzEURYMoWKs_wF3AdTSZdPKxrEP9gKIFK7gLmUyiKemkJjOF_nunVnHl6j149x4eB4BLgq8JxvwmEyyFRJgIJJnkiB2BESk5RVTiyfHvTibyFJzlvMK4LDjBIxAWKTa96XxsYXTwKW5tgJVe2-AbOG07j6q3ak4wfNlY4503cBHDzoTY6vB9r2PjbYa6beBsq0Ovf1HLD-sTvPUxWT3wt77bnYMTp0O2Fz9zDF7vZsvqAc2f7x-r6RwZSliHaGmoJUKIWlpaGGZEwbElThY1I5yWlrFJ4WzJHKuJ4VZzR51xjRCl1JwxOgZXB-4mxc_e5k6tYp-Gj7MqMCmFKEqBhxQ5pEyKOSfr1Cb5tU47RbDaS1UHqWqQqvZS1Z5cHDp5yLbvNv2R_y99Adacee8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015882580</pqid></control><display><type>article</type><title>Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity</title><source>Springer Nature</source><creator>Sadeghian-Rizi, Tahereh ; Behdani, Mahdi ; Khanahmad, Hossein ; Ghasemi-Dehkordi, Pooria ; Mirmohammad Sadeghi, Hamid ; Jahanian-Najafabadi, Ali</creator><creatorcontrib>Sadeghian-Rizi, Tahereh ; Behdani, Mahdi ; Khanahmad, Hossein ; Ghasemi-Dehkordi, Pooria ; Mirmohammad Sadeghi, Hamid ; Jahanian-Najafabadi, Ali</creatorcontrib><description>CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammatory and autoimmune diseases. It has been put forward as a potential biomarker and therapeutic target in diagnosis and treatment of these diseases. In the present study, production of camel heavy chain antibodies (HCAbs) specific for the CXCL10 is reported. In this regard, recombinant CXCL10 was used for immunization of camel and subsequently the CXCL10 HCAbs were obtained. Afterwards, three subclasses of IgG were separated using protein A and protein G affinity columns, characterized with SDS-PAGE and confirmed for specific binding to the CXCL10 using ELISA. These IgG subclasses successfully recognized CXCL10 and a strong and specific reactivity towards CXCL10 were observed. Therefore, the selected HCAbs and their corresponding expression library could be used to develop a recombinant variable domain of these HCAbs (nanobody or VHH) as a new possible strategy for treatment of multiple sclerosis and other autoimmune diseases.</description><identifier>ISSN: 1573-3149</identifier><identifier>EISSN: 1573-3904</identifier><identifier>DOI: 10.1007/s10989-018-9697-6</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animal Anatomy ; Autoimmune diseases ; Biochemistry ; Biomedical and Life Sciences ; Chemokines ; CXC chemokines ; CXCL10 protein ; CXCR3 protein ; Enzyme-linked immunosorbent assay ; Gel electrophoresis ; Histology ; Immunization ; Immunoglobulin G ; Life Sciences ; Medical treatment ; Membrane reactors ; Molecular Medicine ; Morphology ; Multiple sclerosis ; Nanobodies ; Pharmaceutical Sciences/Technology ; Pharmacology/Toxicology ; Polyclonal antibodies ; Polymer Sciences ; Protein G ; Sodium lauryl sulfate ; Therapeutic applications ; γ-Interferon</subject><ispartof>International journal of peptide research and therapeutics, 2019-06, Vol.25 (2), p.535-540</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>International Journal of Peptide Research and Therapeutics is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663</citedby><cites>FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sadeghian-Rizi, Tahereh</creatorcontrib><creatorcontrib>Behdani, Mahdi</creatorcontrib><creatorcontrib>Khanahmad, Hossein</creatorcontrib><creatorcontrib>Ghasemi-Dehkordi, Pooria</creatorcontrib><creatorcontrib>Mirmohammad Sadeghi, Hamid</creatorcontrib><creatorcontrib>Jahanian-Najafabadi, Ali</creatorcontrib><title>Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity</title><title>International journal of peptide research and therapeutics</title><addtitle>Int J Pept Res Ther</addtitle><description>CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammatory and autoimmune diseases. It has been put forward as a potential biomarker and therapeutic target in diagnosis and treatment of these diseases. In the present study, production of camel heavy chain antibodies (HCAbs) specific for the CXCL10 is reported. In this regard, recombinant CXCL10 was used for immunization of camel and subsequently the CXCL10 HCAbs were obtained. Afterwards, three subclasses of IgG were separated using protein A and protein G affinity columns, characterized with SDS-PAGE and confirmed for specific binding to the CXCL10 using ELISA. These IgG subclasses successfully recognized CXCL10 and a strong and specific reactivity towards CXCL10 were observed. Therefore, the selected HCAbs and their corresponding expression library could be used to develop a recombinant variable domain of these HCAbs (nanobody or VHH) as a new possible strategy for treatment of multiple sclerosis and other autoimmune diseases.</description><subject>Animal Anatomy</subject><subject>Autoimmune diseases</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Chemokines</subject><subject>CXC chemokines</subject><subject>CXCL10 protein</subject><subject>CXCR3 protein</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Gel electrophoresis</subject><subject>Histology</subject><subject>Immunization</subject><subject>Immunoglobulin G</subject><subject>Life Sciences</subject><subject>Medical treatment</subject><subject>Membrane reactors</subject><subject>Molecular Medicine</subject><subject>Morphology</subject><subject>Multiple sclerosis</subject><subject>Nanobodies</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Pharmacology/Toxicology</subject><subject>Polyclonal antibodies</subject><subject>Polymer Sciences</subject><subject>Protein G</subject><subject>Sodium lauryl sulfate</subject><subject>Therapeutic applications</subject><subject>γ-Interferon</subject><issn>1573-3149</issn><issn>1573-3904</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEURYMoWKs_wF3AdTSZdPKxrEP9gKIFK7gLmUyiKemkJjOF_nunVnHl6j149x4eB4BLgq8JxvwmEyyFRJgIJJnkiB2BESk5RVTiyfHvTibyFJzlvMK4LDjBIxAWKTa96XxsYXTwKW5tgJVe2-AbOG07j6q3ak4wfNlY4503cBHDzoTY6vB9r2PjbYa6beBsq0Ovf1HLD-sTvPUxWT3wt77bnYMTp0O2Fz9zDF7vZsvqAc2f7x-r6RwZSliHaGmoJUKIWlpaGGZEwbElThY1I5yWlrFJ4WzJHKuJ4VZzR51xjRCl1JwxOgZXB-4mxc_e5k6tYp-Gj7MqMCmFKEqBhxQ5pEyKOSfr1Cb5tU47RbDaS1UHqWqQqvZS1Z5cHDp5yLbvNv2R_y99Adacee8</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Sadeghian-Rizi, Tahereh</creator><creator>Behdani, Mahdi</creator><creator>Khanahmad, Hossein</creator><creator>Ghasemi-Dehkordi, Pooria</creator><creator>Mirmohammad Sadeghi, Hamid</creator><creator>Jahanian-Najafabadi, Ali</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20190601</creationdate><title>Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity</title><author>Sadeghian-Rizi, Tahereh ; Behdani, Mahdi ; Khanahmad, Hossein ; Ghasemi-Dehkordi, Pooria ; Mirmohammad Sadeghi, Hamid ; Jahanian-Najafabadi, Ali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animal Anatomy</topic><topic>Autoimmune diseases</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Chemokines</topic><topic>CXC chemokines</topic><topic>CXCL10 protein</topic><topic>CXCR3 protein</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Gel electrophoresis</topic><topic>Histology</topic><topic>Immunization</topic><topic>Immunoglobulin G</topic><topic>Life Sciences</topic><topic>Medical treatment</topic><topic>Membrane reactors</topic><topic>Molecular Medicine</topic><topic>Morphology</topic><topic>Multiple sclerosis</topic><topic>Nanobodies</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Pharmacology/Toxicology</topic><topic>Polyclonal antibodies</topic><topic>Polymer Sciences</topic><topic>Protein G</topic><topic>Sodium lauryl sulfate</topic><topic>Therapeutic applications</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sadeghian-Rizi, Tahereh</creatorcontrib><creatorcontrib>Behdani, Mahdi</creatorcontrib><creatorcontrib>Khanahmad, Hossein</creatorcontrib><creatorcontrib>Ghasemi-Dehkordi, Pooria</creatorcontrib><creatorcontrib>Mirmohammad Sadeghi, Hamid</creatorcontrib><creatorcontrib>Jahanian-Najafabadi, Ali</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Science Database (ProQuest)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>International journal of peptide research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sadeghian-Rizi, Tahereh</au><au>Behdani, Mahdi</au><au>Khanahmad, Hossein</au><au>Ghasemi-Dehkordi, Pooria</au><au>Mirmohammad Sadeghi, Hamid</au><au>Jahanian-Najafabadi, Ali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity</atitle><jtitle>International journal of peptide research and therapeutics</jtitle><stitle>Int J Pept Res Ther</stitle><date>2019-06-01</date><risdate>2019</risdate><volume>25</volume><issue>2</issue><spage>535</spage><epage>540</epage><pages>535-540</pages><issn>1573-3149</issn><eissn>1573-3904</eissn><abstract>CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammatory and autoimmune diseases. It has been put forward as a potential biomarker and therapeutic target in diagnosis and treatment of these diseases. In the present study, production of camel heavy chain antibodies (HCAbs) specific for the CXCL10 is reported. In this regard, recombinant CXCL10 was used for immunization of camel and subsequently the CXCL10 HCAbs were obtained. Afterwards, three subclasses of IgG were separated using protein A and protein G affinity columns, characterized with SDS-PAGE and confirmed for specific binding to the CXCL10 using ELISA. These IgG subclasses successfully recognized CXCL10 and a strong and specific reactivity towards CXCL10 were observed. Therefore, the selected HCAbs and their corresponding expression library could be used to develop a recombinant variable domain of these HCAbs (nanobody or VHH) as a new possible strategy for treatment of multiple sclerosis and other autoimmune diseases.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><doi>10.1007/s10989-018-9697-6</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1573-3149
ispartof International journal of peptide research and therapeutics, 2019-06, Vol.25 (2), p.535-540
issn 1573-3149
1573-3904
language eng
recordid cdi_proquest_journals_2015882580
source Springer Nature
subjects Animal Anatomy
Autoimmune diseases
Biochemistry
Biomedical and Life Sciences
Chemokines
CXC chemokines
CXCL10 protein
CXCR3 protein
Enzyme-linked immunosorbent assay
Gel electrophoresis
Histology
Immunization
Immunoglobulin G
Life Sciences
Medical treatment
Membrane reactors
Molecular Medicine
Morphology
Multiple sclerosis
Nanobodies
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Polyclonal antibodies
Polymer Sciences
Protein G
Sodium lauryl sulfate
Therapeutic applications
γ-Interferon
title Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Production%20of%20Novel%20Camelid%20Anti-CXCL10%20Specific%20Polyclonal%20Antibodies%20and%20Evaluation%20of%20Their%20Bioreactivity&rft.jtitle=International%20journal%20of%20peptide%20research%20and%20therapeutics&rft.au=Sadeghian-Rizi,%20Tahereh&rft.date=2019-06-01&rft.volume=25&rft.issue=2&rft.spage=535&rft.epage=540&rft.pages=535-540&rft.issn=1573-3149&rft.eissn=1573-3904&rft_id=info:doi/10.1007/s10989-018-9697-6&rft_dat=%3Cproquest_cross%3E2015882580%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c316t-35c3e1888b9e32c6c8270e1f92b61735e6642fe56f6b1c7ea7f3fcfd8859a7663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2015882580&rft_id=info:pmid/&rfr_iscdi=true